Showing results (121-130 of 447) with videos related to
Sort By:
Pageof 45
Cancer Science|April 12, 2020
CD20+ tumor-infiltrating immune cells and CD204+ M2 macrophages are associated with prognosis in thymic carcinomaJun Sato, Shigehisa Kitano, Noriko Motoi, et al.Internal Medicine (Tokyo, Japan)|February 18, 2011
Development of Cushing's syndrome during effective chemotherapy for small cell lung cancerKoichi Suyama, Yoichi Naito, Kiyotaka Yoh, et al.Japanese Journal of Clinical Oncology|April 7, 2004
Randomized trial of oral versus intravenous antibiotics in low-risk febrile neutropenic patients with lung cancerSeiji Niho, Yuichiro Ohe, Koichi Goto, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 2, 2008
Influence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small cell lung cancer patientsYasushi Goto, Ikuo Sekine, Kazuhiko Yamada, et al.Japanese Journal of Clinical Oncology|October 22, 2014
A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201)Junko Eba, Tsuneo Shimokawa, Kenichi Nakamura, et al.Lung Cancer (Amsterdam, Netherlands)|March 15, 2025
Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinomaMasahiro Torasawa, Tatsuya Yoshida, Kouya Shiraishi, et al.Cancer Science|February 11, 2012
Brain metastases after definitive concurrent chemoradiotherapy in patients with stage III lung adenocarcinoma: carcinoembryonic antigen as a potential predictive factorHidehito Horinouchi, Ikuo Sekine, Minako Sumi, et al.Oncology|October 2, 2008
Gender differences in treatment outcomes among patients with non-small cell lung cancer given a combination of carboplatin and paclitaxelHarukaze Yamamoto, Ikuo Sekine, Kazuhiko Yamada, et al.Japanese Journal of Clinical Oncology|February 28, 2013
Renal toxicity caused by brand-name versus generic cisplatin: a comparative analysisSeiji Niho, Takeharu Yamanaka, Shigeki Umemura, et al.Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancerKatsutoshi Sekine, Shintaro Kanda, Yasushi Goto, et al.Pageof 45